nach oben

Clinical and Translational Oncology

Erschienen in:

01.12.2013 | Clinical Guides in Oncology

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

verfasst von: J. Maurel, C. Grávalos, F. Rivera, R. Vera, E. González Flores

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is one of the most important causes of cancer mortality worldwide. This article reviews the available evidence for optimum management of stage II and III colorectal cancer, with respect to staging, surgical and adjuvant neoadjuvant treatment.

Nur mit Berechtigung zugänglich

Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Chichester: Wiley-Blackwell; 2009.

Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357:497–504.PubMedCrossRef

Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97:219–25.PubMedCrossRef

Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, Haglind E, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Colon Cancer Laparoscopic or Open Resection Study Group. Lancet Oncol. 2009;10(1):44–52.PubMedCrossRef

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.PubMedCrossRef

Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O’Connell MJ, Yothers G. A phase III trial comparing 5FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol. 2008;26(15S):LBA4005.

Haller D, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Adjuvant treatment with capecitabine and oxaliplatin (XELOX) in stage III colon cancer. Berlin: ESMO/ECCO Presidential Session III; 2009.

McCleary NA, Meyerhardt J, Green E, Yothers G, de Gramont A, Van Cutsem E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol. 2009;27:15s (suppl; abstr 4010).CrossRef

Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059–64.PubMedCrossRef

10.

Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.PubMedCrossRef

11.

Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.PubMedCrossRef

12.

Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117–25.PubMedCrossRef

13.

Wolmark N, Yothers G, O’Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing FOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27(15S):LBA4.

14.

Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.PubMedCrossRef

15.

Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253:711–9.PubMedCrossRef

16.

Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.PubMedCrossRef

17.

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRef

18.

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRef

19.

Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.PubMedCrossRef

20.

Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579–88.PubMedCrossRef

21.

Roh MS, Yothers GA, O’Connell MJ, Beart RW, Pitot NC, Shields AF et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. In: Proceedings of ASCO 3503; 2011.

22.

Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng CA, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770–6.PubMedCrossRef

23.

Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010;21:1743–50.PubMedCrossRef

24.

Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;1:CD002200.PubMed

25.

Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, et al. American Cancer Society; US Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130(6):1865–71.PubMedCrossRef

Titel: SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013
verfasst von: J. Maurel
C. Grávalos
F. Rivera
R. Vera
E. González Flores
Publikationsdatum: 01.12.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1083-4

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

Abstract

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

SEOM clinical guidelines for the treatment of small-cell lung cancer 2013

SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013

SEOM Guidelines 2013: a response to the needs of Spanish oncologists

SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie